Top Markets
#1 Akedo Akedo +73.50%
#2 MEET48 MEET48 +26.11%
#3 Bitway Bitway +21.76%
#4 VeThor VeThor +21.08%
#5 Power Protocol Power Protocol +17.38%
#6 Tutorial Tutorial +16.23%
#7 Astar Astar +14.86%
#8 龙虾 (Lobster) 龙虾 (Lobster) +12.72%
#9 Falcon Finance Falcon Finance +12.11%
#10 Arbitrum Arbitrum +12.09%
Coin of the day
Akedo Akedo
設定
言語
日本
通貨
USD
テーマ
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
株式のランク #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
株価
$0.25974701
最終同期: 2025-01-06
時価総額
$2.04M
変化（1日）
0.74%
変化（1年）
0.00%
国
FR
取引 Acticor Biotech SAS (ALACT)

カテゴリー

Healthcare
Acticor Biotech SAS（ALACT）の株式分割履歴
Acticor Biotech SAS株（シンボル：ALACT）は合計で0回の株式分割を実施しました。
最新の株式分割はSep 15, 2026に行われました。
Sep 15, 2026より前に購入されたALACT株は、現在0ALACT株に相当します。
株式分割一覧
年 株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH